跳至主要内容
临床试验/JPRN-jRCTs031220683
JPRN-jRCTs031220683招募中2 期

Investigation of efficacy and safety of Sequence treatment of Cabazitaxel administation after 3 courses of Docetaxel for castration-resistant prostate cancer

Taguchi Satoru0 个研究点目标入组 20 人开始时间: 2023年3月3日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable(—)
性别
Male

入选标准

  • (1) Diagnosed with metastatic castrate-resistant prostate cancer
  • (2) Scheduled to take docetaxel
  • (3) Male, aged 18 years and above at the time of informed consent
  • (4) Able and willing to give written informed consent with sufficient understanding after having received sufficient explanation
  • (5) Able to attend all scheduled visits

排除标准

  • (1) With chemotherapy intolerance
  • (2) With a history of taking docetaxel or cabazitaxel
  • (3) With severe liver failure, renal failure, or cardiac disease (judged by CTCAE v5.0-JCOG grade 3)
  • (4) With severe myelosuppression (judged by CTCAE v5.0-JCOG grade 3)
  • (5) With systemic infection
  • (6) Suspected of infectious disease with fever
  • (7) Suspected of intestinal pneumonia
  • (8) With a history of severe allergy to docetaxel, cabazitaxel, or drugs containing polysorbate 80
  • (9) With malignancy other than prostate cancer
  • (10) With a history of severe drug allergy including anaphylactic shock, or a history of severe side effects
  • (11) Judged as ineligible by clinical investigators

研究者

发起方
Taguchi Satoru

相似试验